支架内再狭窄非编码核糖核酸靶向治疗研究进展

Advances in non-coding ribonucleic acid-targeted therapy for in-stent restenosis

血管内支架植入术作为一种微创、安全有效的方法,近年来广泛应用于下肢动脉硬化闭塞症(ASO)治疗,但支架内再狭窄(ISR)(血管直径缩小至参考血管直径50%以上)发生率仍然很高。因此,如何治疗ISR成为临床主要问题。非编码核糖核酸(ncRNA)是一类不编码蛋白质核糖核酸(RNA)分子,如微RNA(microRNA,miRNA)、环状RNA(circRNA)、长链非编码RNA(lncRNA)的统称,可调节ncRNA中血管平滑肌细胞表型转化,如增殖、迁移、凋亡、新生内膜增殖等。该文举例说明了ncRNA作为ISR治疗可能的生物标志物或潜在治疗靶标,并阐述了相关新思想和新发现。

Being a minimally invasive,safe and effective therapy,endovascular stenting has been widely used in the treatment of lower limb arteriosclerosis obliterans(ASO)in recent years,but the incidence of in-stent restenosis(ISR,i.e.the reduction of the vascular diameter>50%of the reference vessel diameter)is rather high.Therefore,how to treat ISR has become a major clinical issue.Non-coding ribonucleic acid(ncRNA)is a generic term for a group of RNA molecules that do not encode proteins,such as microRNA(miRNA),circle RNA(circRNA),long-chain non-coding RNA(lncRNA),which can regulate the phenotypic transformation of vascular smooth muscle cells in ncRNA,e.g.proliferation,migration,apoptosis,neointimal proliferation,etc.This paper aims to illustrate the value of ncRNA(as a possible biomarker or potential therapeutic target)and to expound the relevant new ideas and discoveries in the treatment of ISR.